Menu
Recruiting NCT06719583

Black and African Americans Connections to Parkinson's Disease (BLAAC PD)

— Observational Parkinson Disease

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
This is an observational study: the protocol does not assign a study treatment.
Who it may be relevant to
Registry conditions: Parkinson Disease. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United States
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

Black and African Americans Connections to Parkinson's Disease (BLAAC PD) A Project of the Global Parkinson's Genetics Program (GP2)

Overview

BLAAC PD is a research study to understand what Parkinson's disease looks like for Black and African American communities. BLAAC PD is happening at research centers around the United States. The study is part of the Global Parkinson's Genetics Program (GP2). GP2 is a research project working to transform understanding of the genetics of Parkinson's disease and make that knowledge globally relevant.

Detailed description

Research studies have found connections between genes and Parkinson's disease (PD). But those results have mostly come from studies with non-Black or African American volunteers. BLAAC PD aims to learn more about gene changes that may cause Parkinson's in Black and African American people. Study volunteers at sites across the United States will attend one visit and will give either a blood or saliva sample, complete a smell test, and may be asked to complete a physical exam. This new data could lead to future Parkinson's tests and treatments for Black and African American people and it may help better understand disease in other groups, too.

This pioneering initiative will fill a gap of knowledge about PD in Black and African American people.

Primary outcome measures

  • Explore novel risk factors and characterization [Time frame: 5 years]

Eligibility criteria

Inclusion Criteria for Control Participants:

  • Ability to provide informed consent
  • Age 50 years or older
  • Self-identify as Black or African American

Exclusion Criteria for Control Participants:

  • Diagnosis of Parkinson's Disease and/or neurological condition
  • Familial history of PD and/or neurodegenerative or psychiatric conditions
  • Unknown family history of PD and/or neurodegenerative or psychiatric conditions
  • Any conditions that, in the investigator's opinion, preclude the individual's ability to carry out study activities
  • If submitting a saliva sample, nothing by mouth (food, drink, gum, tobacco, or smoking) for 30 minutes prior to sample collection

Inclusion Criteria for Participants with a Diagnosis of PD:

  • Ability to provide informed consent
  • Age 18 years or older
  • Self-identify as Black or African American
  • Meet the Movement Disorder Society's clinical diagnostic criteria for Parkinson's disease

Exclusion Criteria for Participants with a Diagnosis of PD:

\- If submitting a saliva sample, nothing by mouth (food, drink, gum, tobacco, or smoking) for 30 minutes prior to sample collection

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: Yes

Study design

Observational model
Case-control

Study locations

United States · 12 centers
  • University of Alabama at Birmingham — Birmingham
  • University of Florida — Gainesville
  • Rush University — Chicago
  • University of Chicago — Chicago
  • Ochsner Clinic Foundation — New Orleans
  • Louisiana State University Health Sciences Center Shreveport — Shreveport
  • University of Maryland — Baltimore
  • Kaiser Permanente Midatlantic States — Rockville
  • … and 4 more centers

Publications

  • Chahine LM, Louie N, Solle J, Akcimen F, Ameri A, Augenbraun S, Avripas S, Breaux S, Causey C, Chandra S, Dean M, Disbrow EA, Fanty L, Fernandez J, Foster ER, Furr Stimming E, Hall D, Hinson V, Johnson-Turbes A, Jonas C, Kilbane C, Norris SA, Nguyen BT, Padmanaban M, Paquette K, Parry C, Pessoa Rocha N, Rawls A, Shamim EA, Shulman LM, Sipma R, Staisch J, Traurig R, von Coelln R, Wild Crea P, Xie T PMID 39434044

Identifiers

NCT: NCT06719583 · BLAAC PD

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗